Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Acta Neuropathologica
Published in: Acta Neuropathologica 4/2011

01-10-2011 | Original Paper

Factors affecting Aβ plasma levels and their utility as biomarkers in ADNI

Authors: Jon B. Toledo, Hugo Vanderstichele, Michal Figurski, Paul S. Aisen, Ronald C. Petersen, Michael W. Weiner, Clifford R. Jack Jr, William Jagust, Charles Decarli, Arthur W. Toga, Estefanía Toledo, Sharon X. Xie, Virginia M.-Y. Lee, John Q. Trojanowski, Leslie M. Shaw

Published in: Acta Neuropathologica | Issue 4/2011

Login to get access

Abstract

Previous studies of Aβ plasma as a biomarker for Alzheimer’s disease (AD) obtained conflicting results. We here included 715 subjects with baseline Aβ1-40 and Aβ1-42 plasma measurement (50% with 4 serial annual measurements): 205 cognitively normal controls (CN), 348 patients mild cognitive impairment (MCI) and 162 with AD. We assessed the factors that modified their concentrations and correlated these values with PIB PET, MRI and tau and Aβ1-42 measures in cerebrospinal fluid (CSF). Association between Aβ and diagnosis (baseline and prospective) was assessed. A number of health conditions were associated with altered concentrations of plasma Aβ. The effect of age differed according to AD stage. Plasma Aβ1-42 showed mild correlation with other biomarkers of Aβ pathology and were associated with infarctions in MRI. Longitudinal measurements of Aβ1-40 and Aβ1-42 plasma levels showed modest value as a prognostic factor for clinical progression. Our longitudinal study of complementary measures of Aβ pathology (PIB, CSF and plasma Aβ) and other biomarkers in a cohort with an extensive neuropsychological battery is significant because it shows that plasma Aβ measurements have limited value for disease classification and modest value as prognostic factors over the 3-year follow-up. However, with longer follow-up, within subject plasma Aβ measurements could be used as a simple and minimally invasive screen to identify those at increased risk for AD. Our study emphasizes the need for a better understanding of the biology and dynamics of plasma Aβ as well as the need for longer term studies to determine the clinical utility of measuring plasma Aβ.
Appendix
Available only for authorised users
Literature
1.
(1998) Consensus report of the Working Group on: “Molecular and Biochemical Markers of Alzheimer’s Disease”. The Ronald and Nancy Reagan Research Institute of the Alzheimer’s Association and the National Institute on Aging Working Group. Neurobiology of aging 19(2): 109–116
2.
Alexander G, Furey M, Grady C et al (1997) Association of premorbid intellectual function with cerebral metabolism in Alzheimer’s disease: implications for the cognitive reserve hypothesis. Am J Psychiatry 154(2):165–172PubMed
3.
Arvanitakis Z, Lucas JA, Younkin LH, Younkin SG, Graff-Radford NR (2002) Serum creatinine levels correlate with plasma amyloid [beta] protein. Alzheimer Dis Assoc Disord 16(3):187–190PubMedCrossRef
4.
Blasko I, Kemmler G, Krampla W et al (2005) Plasma amyloid [beta] protein 42 in non-demented persons aged 75 years: effects of concomitant medication and medial temporal lobe atrophy. Neurobiol Aging 26(8):1135–1143PubMedCrossRef
5.
Blennow K, De Meyer G, Hansson O et al (2009) Evolution of Abeta42 and Abeta40 levels and Abeta42/Abeta40 ratio in plasma during progression of Alzheimer’s disease: a multicenter assessment. J Nutr Health Aging 13(3):205–208PubMedCrossRef
6.
Butters N, Granholm E, Salmon D, Grant I, Wolfe J (1987) Episodic and semantic memory: a comparison of amnesic and demented patients. J Clin Exp Neuropsychol 9(5):479–497PubMedCrossRef
7.
Carmichael O, Schwarz C, Drucker D et al (2010) Longitudinal changes in white matter disease and cognition in the first year of the alzheimer disease neuroimaging initiative. Arch Neurol 67(11):1370–1378PubMedCrossRef
8.
Cosentino SA, Stern Y, Sokolov E et al (2010) Plasma {beta}-amyloid and cognitive decline. Arch Neurol 67(12):1485–1490PubMedCrossRef
9.
Chen M, Inestrosa NC, Ross GS, Fernandez HL (1995) Platelets are the primary source of amyloid [beta]-peptide in human blood. Biochem Biophys Res Commun 213(1):96–103PubMedCrossRef
10.
Davatzikos C, Bhatt P, Shaw LM, Batmanghelich KN and Trojanowski JQ (2010) Prediction of MCI to AD conversion, via MRI, CSF biomarkers, and pattern classification. Neurobiol aging
11.
de Souza LC, Lamari F, Belliard S et al (2011) Cerebrospinal fluid biomarkers in the differential diagnosis of Alzheimer’s disease from other cortical dementias. J Neurol Neurosurg Psychiatry 82(3):240–246PubMedCrossRef
12.
Devanand DP, Schupf N, Stern Y et al (2011) Plasma Aβ and PET PiB binding are inversely related in mild cognitive impairment. Neurology
13.
Fagan AM, Mintun MA, Shah AR et al (2009) Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer’s disease. EMBO Mol Med 1(8–9):371–380PubMedCrossRef
14.
Fagan AM, Shaw LM, Xiong C et al (2011) Comparison of Analytical Platforms for Cerebrospinal Fluid Measures of {beta}-Amyloid 1-42, Total tau, and P-tau181 for Identifying Alzheimer Disease Amyloid Plaque Pathology. Arch Neurol
15.
Fei M, Jianghua W, Rujuan M, Wei Z, Qian W (2011) The relationship of plasma A[beta] levels to dementia in aging individuals with mild cognitive impairment. J Neurol Sci 305(1–2):92–96PubMedCrossRef
16.
Folstein MF, Folstein SE, McHugh PR (1975) Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12(3):189–198PubMedCrossRef
17.
Fukumoto H, Tennis M, Locascio JJ et al (2003) Age but not diagnosis is the main predictor of plasma amyloid {beta}-protein levels. Arch Neurol 60(7):958–964PubMedCrossRef
18.
Goldberg KM, Iglewicz B (1992) Bivariate extensions of the boxplot. Technometrics 34:307–320CrossRef
19.
Goodglass H, Kaplan E (1983) The assessment of aphasia and related disorders. Lea & Febiger, Philadelphia
20.
Graff-Radford NR, Crook JE, Lucas J et al (2007) Association of low plasma Abeta42/Abeta40 Ratios with increased imminent risk for mild cognitive impairment and alzheimer disease. Arch Neurol 64(3):354–362PubMedCrossRef
21.
Gurol ME, Irizarry MC, Smith EE et al (2006) Plasma β-amyloid and white matter lesions in AD, MCI, and cerebral amyloid angiopathy. Neurology 66(1):23–29PubMedCrossRef
22.
Ikonomovic MD, Klunk WE, Abrahamson EE et al (2008) Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer’s disease. Brain 131(6):1630–1645PubMedCrossRef
23.
Jack CR Jr, Bernstein MA, Fox NC et al (2008) The Alzheimer’s disease neuroimaging initiative (ADNI): MRI methods. J Magn Reson Imaging 27(4):685–691PubMedCrossRef
24.
Jack CR Jr, Knopman DS, Jagust WJ et al (2010) Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade. Lancet Neurol 9(1):119–128PubMedCrossRef
25.
Jagust WJ, Bandy D, Chen K et al (2010) The Alzheimer’s disease neuroimaging Initiative positron emission tomography core. Alzheimers Dement 6(3):221–229PubMedCrossRef
26.
Kaplan E, Goodglass H, Weintraub S (1983) Boston naming test. Lea & Febiger, Philadelphia
27.
Lachno DR, Vanderstichele H, De Groote G et al (2009) The influence of matrix type, diurnal rhythm and sample collection and processing on the measurement of plasma beta-amyloid isoforms using the INNO-BIA plasma Abeta forms multiplex assay. J Nutr Health Aging 13(3):220–225PubMedCrossRef
28.
Lambert J-C, Schraen-Maschke S, Richard F et al (2009) Association of plasma amyloid β with risk of dementia. Neurology 73(11):847–853PubMedCrossRef
29.
Lambert JC, Dallongeville J, Ellis KA et al (2011) Association of plasma aβ peptides with blood pressure in the elderly. PLoS ONE 6(4):e18536PubMedCrossRef
30.
Laske C, Sopova K, Gkotsis C et al (2010) Amyloid-β peptides in plasma and cognitive decline after 1 year follow-up in alzheimer’s disease patients. J Alzheimers Dis 21(4):1263–1269PubMed
31.
Lewczuk P, Kornhuber J, Vanmechelen E et al (2010) Amyloid beta peptides in plasma in early diagnosis of Alzheimer’s disease: a multicenter study with multiplexing. Exp Neurol 223(2):366–370PubMedCrossRef
32.
Locascio JJ, Fukumoto H, Yap L et al (2008) Plasma amyloid {beta}-protein and c-reactive protein in relation to the rate of progression of Alzheimer disease. Arch Neurol 65(6):776–785PubMedCrossRef
33.
Lopez OL, Kuller LH, Mehta PD et al (2008) Plasma amyloid levels and the risk of AD in normal subjects in the Cardiovascular Health Study. Neurology 70(19):1664–1671PubMedCrossRef
34.
Lui JK, Laws SM, Li Q-X et al (2010) Plasma amyloid-β as a biomarker in Alzheimer’s disease: the AIBL study of aging. J Alzheimers Dis 20(4):1233–1242PubMed
35.
Mathis CA, Wang Y, Holt DP et al (2003) Synthesis and Evaluation of 11C-Labeled 6-Substituted 2-Arylbenzothiazoles as Amyloid Imaging Agents. J Med Chem 46(13):2740–2754PubMedCrossRef
36.
Mayeux R, Tang M-X, Jacobs DM et al (1999) Plasma amyloid β-peptide 1-42 and incipient Alzheimer’s disease. Ann Neurol 46(3):412–416PubMedCrossRef
37.
Mayeux R, Honig LS, Tang M-X et al (2003) Plasma Aβ40 and Aβ42 and Alzheimer’s disease: relation to age, mortality, and risk. Neurology 61(9):1185–1190PubMed
38.
Mehta PD, Pirttila T, Patrick BA, Barshatzky M, Mehta SP (2001) Amyloid [beta] protein 1-40 and 1-42 levels in matched cerebrospinal fluid and plasma from patients with Alzheimer disease. Neurosci Lett 304(1–2):102–106PubMedCrossRef
39.
Petersen RC, Aisen PS, Beckett LA et al (2010) Alzheimer’s disease neuroimaging initiative (ADNI): clinical characterization. Neurology 74(3):201–209PubMedCrossRef
40.
41.
Reitan R (1958) Validity of the trail making test as an indicator of organic brain damage. Percept Mot Skills 8:271–276
42.
Rentz DM, Locascio JJ, Becker JA et al (2010) Cognition, reserve, and amyloid deposition in normal aging. Ann Neurol 67(3):353–364PubMedCrossRef
43.
Rey A (1964) L’examen clinique en psychologie. Presses Universitaires de France, Paris
44.
Rosen W, Mohs R, Davis K (1984) A new rating scale for Alzheimer’s disease. Am J Psychiatry 141(11):1356–1364PubMed
45.
Ryan JR, Paolo AM (1992) A screening procedure for estimating premorbid intelligence in the elderly. Clin Neuropsychol 6(1):53–62CrossRef
46.
Schupf N, Tang MX, Fukuyama H et al (2008) Peripheral Aβ subspecies as risk biomarkers of Alzheimer’s disease. Proc Nat Acad Sci 105(37):14052–14057PubMedCrossRef
47.
Schupf N, Zigman WB, Tang M-X et al (2010) Change in plasma Aβ peptides and onset of dementia in adults with Down syndrome. Neurology 75(18):1639–1644PubMedCrossRef
48.
Seppälä TT, Herukka S-K, Hänninen T et al (2010) Plasma Aβ42 and Aβ40 as markers of cognitive change in follow-up: a prospective, longitudinal, population-based cohort study. J Neurol Neurosurg Psychiatry 81(10):1123–1127PubMedCrossRef
49.
Shaw LM, Vanderstichele H, Knapik-Czajka M et al (2009) Cerebrospinal fluid biomarker signature in Alzheimer’s disease neuroimaging initiative subjects. Ann Neurol 65(4):403–413PubMedCrossRef
50.
Shaw LM, Vanderstichele H, Knapik-Czajka M et al (2011) Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI. Acta Neuropathol 121(5):597–609PubMedCrossRef
51.
Song F, Poljak A, Valenzuela M, et al (2011) Meta-Analysis of Plasma Amyloid-beta levels in Alzheimer’s Disease. J Alzheimers Dis (1875-8908 (Electronic))
52.
Sundelof J, Giedraitis V, Irizarry MC et al (2008) Plasma beta amyloid and the risk of alzheimer disease and dementia in elderly men: a prospective, population-based cohort study. Arch Neurol 65(2):256–263PubMedCrossRef
53.
Taylor K, Salmon D, Rice V et al (1996) Longitudinal examination of american national adult reading test (AMNART) performance in dementia of the Alzheimer type (DAT): validation and correction based on degree of cognitive decline. J Clin Exp Neuropsychol 18(6):883–891PubMedCrossRef
54.
Van Dijk EJ, Prins ND, Vermeer SE et al (2004) Plasma amyloid β, apolipoprotein E, lacunar infarcts, and white matter lesions. Ann Neurol 55(4):570–575PubMedCrossRef
55.
van Oijen M, Hofman A, Soares HD, Koudstaal PJ, Breteler MM (2006) Plasma Abeta(1-40) and Abeta(1-42) and the risk of dementia: a prospective case-cohort study. Lancet Neurol 5(8):655–660PubMedCrossRef
56.
Wechsler D (1987) Wechsler Memory Scale. Rev ed. Psychological Corp, San Antonio
57.
Weigand SD, Vemuri P, Wiste HJ et al (2011) Transforming cerebrospinal fluid Abeta42 measures into calculated Pittsburgh compound B units of brain Abeta amyloid. Alzheimers Dement 7(2):133–141PubMedCrossRef
58.
59.
Yaffe K, Weston A, Graff-Radford NR et al (2011) Association of plasma β-amyloid level and cognitive reserve with subsequent cognitive decline. JAMA 305(3):261–266PubMedCrossRef
Metadata
Title
Factors affecting Aβ plasma levels and their utility as biomarkers in ADNI
Authors
Jon B. Toledo
Hugo Vanderstichele
Michal Figurski
Paul S. Aisen
Ronald C. Petersen
Michael W. Weiner
Clifford R. Jack Jr
William Jagust
Charles Decarli
Arthur W. Toga
Estefanía Toledo
Sharon X. Xie
Virginia M.-Y. Lee
John Q. Trojanowski
Leslie M. Shaw
Publication date
01-10-2011
Publisher
Springer-Verlag
Published in
Acta Neuropathologica / Issue 4/2011
Print ISSN: 0001-6322
Electronic ISSN: 1432-0533
DOI
https://doi.org/10.1007/s00401-011-0861-8

Other articles of this Issue 4/2011

Acta Neuropathologica 4/2011 Go to the issue

Correspondence

Complex tauopathies versus tangle predominant dementia

Original Paper

Enhancement of endogenous neurogenesis in ephrin-B3 deficient mice after transient focal cerebral ischemia

Correspondence

Complex tauopathies vs. tangle predominant dementia

Original Paper

Expression of the progenitor marker NG2/CSPG4 predicts poor survival and resistance to ionising radiation in glioblastoma

Original Paper

Effect of ionizing radiation in sensory ganglion neurons: organization and dynamics of nuclear compartments of DNA damage/repair and their relationship with transcription and cell cycle

Original Paper

Treatment of cerebral ischemia with melanocortins acting at MC4 receptors induces marked neurogenesis and long-lasting functional recovery